Issues in Clinical Trial Design-Lessons From the FDA's Rejection of MDMA.
Sign Up to like & getrecommendations! Published in 2025 at "JAMA psychiatry"
DOI: 10.1001/jamapsychiatry.2025.0442
Abstract: This Viewpoint explores potential justifications underlying the US Food and Drug Administration (FDA)’s rejection of methylenedioxymethamphetamine (MDMA) as a treatment for posttraumatic stress disorder, including lack of blinding and issues around the integrity of relevant… read more here.
Keywords: mdma; clinical trial; rejection; fda rejection ... See more keywords